Liu, Xiaolei
De la Cruz, Ester
Gu, Xiaowu http://orcid.org/0000-0003-2266-5516
Balint, Laszlo http://orcid.org/0000-0002-3142-4071
Oxendine-Burns, Michael http://orcid.org/0000-0002-8054-0757
Terrones, Tamara
Ma, Wanshu
Kuo, Hui-Hsuan http://orcid.org/0000-0001-8266-7105
Lantz, Connor http://orcid.org/0000-0003-3317-6486
Bansal, Trisha
Thorp, Edward http://orcid.org/0000-0003-1387-7058
Burridge, Paul http://orcid.org/0000-0001-9616-0006
Jakus, Zoltán http://orcid.org/0000-0002-6304-2369
Herz, Joachim
Cleaver, Ondine
Torres, Miguel http://orcid.org/0000-0003-0906-4767
Oliver, Guillermo http://orcid.org/0000-0003-3984-7615
Article History
Received: 13 June 2019
Accepted: 7 October 2020
First Online: 9 December 2020
Competing interests
: J.H. is a shareholder of Reelin Therapeutics and a co-inventor on a pending US patent application filed by his institution (UT Southwestern; application number 15/763,047 and publication number 20180273637, title “Methods and Compositions for Treatment of Atherosclerosis”; Inventors: J.H., Y. Ding, X. Xian, L. Huang, C. Mineo, P. Shaul and L. Calvier). This patent application covers no aspects of the current manuscript. Findings regarding the potential applications and methods for using RELN to treat cardiac diseases are the subject of provisional patent application (US63/091,558) owned by Northwestern University and list X.L. and G.O. as inventors. All other authors declare no competing interests.